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Should Intravenous n-Acetylcysteine
Be Considered Standard of
Care for Prevention of
Radio-Contrast–Induced Nephropathy?
Baker et al. (1) in a recent issue of the Journal reported results from
the RAPPID trial, which tested the hypothesis that intravenous
(IV) administration of n-acetylcysteine (NAC) with saline was
superior to saline hydration alone for emergent procedures. The
investigators concluded that IV NAC should be considered for all
patients at risk for radiocontrast-induced nephropathy (RCIN)
when time precludes oral prophylaxis. Although this trial encour-
ages further research into the use of IV NAC for prevention of
RCIN, several questions must be answered before IV NAC should
be considered standard of care, particularly in the U.S.
Comparing a high-dose IV NAC regimen with hydration alone,
the researchers found that the risks of RCIN were decreased in
patients receiving IV NAC. These findings are similar to others
utilizing oral NAC prophylaxis, although in most cases the
regimen was initiated several hours prior to a planned procedure
(2–4). Data evaluating the use of oral NAC immediately prior to
a procedure are limited (4,5). Diaz-Sandoval et al. (4) compared
oral NAC with placebo in the APART trial, reporting significant
results favoring the oral NAC regimen. Durham et al. (5) did not
report benefits from oral NAC 1200 mg given 1 h prior to and 3 h
after a procedure when compared with placebo and hydration
alone. It is unclear whether the unique oral NAC regimen or the
volume of saline hydration used contributed to negative results.
Inclusion of an oral NAC regimen as a comparative arm in the
RAPPID trial would have been helpful in clarifying whether an IV
NAC regimen offers advantages over oral administration.
Intravenous NAC is not commercially available in the U.S., and
although some support the IV use of the inhalation solution for
acetaminophen overdose, such regimens are infrequently used in
the U.S. (6). If used, the inhalational solution should be filtered
using a 0.22-m filter to assure product sterility (7); however, U.S.
products are not currently tested for pyrogens or bacterial endo-
toxins, which would not be removed using this process (personal
communication, Bristol-Myers Squibb Company, and American
Regent Laboratories, July 2003).
Dribben et al. (7) recently reported the stability of inhalational
NAC when compounded in 5% dextrose (D5W). Stability data
using inhalational NAC in solutions other than D5W are limited,
although RAPPID investigators used saline. The rate and volume
of normal saline used as the diluent in this study may have
contributed to their positive findings. Clinicians using IV NAC
must proactively determine whether the most widely accepted
diluent in the U.S. should be used, and whether adjunctive saline
hydration has the potential to increase the incidence of adverse
outcomes observed in the RAPPID trial if D5W is chosen as a
diluent.
Until data establishing the appropriate dose and safety of
inhalational NAC administered IV are available, we recommend
administration of saline hydration in conjunction with immediate
initiation of oral NAC 600 mg twice daily for four doses in patients
undergoing emergent procedures. This regimen appears to be safe,
inexpensive, and effective for minimizing the risk of RCIN.
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REPLY
We understand that intravenous (IV) n-acetylcysteine (NAC) as
used in our study (Celltech Pharmaceuticals, Berkshire, SL1 3WE,
United Kingdom) is not available in the U.S. We agree with
Huxtable and colleagues’ concerns over the use of inhalational
NAC for the prevention of radiocontrast-induced nephropathy
(RCIN), particularly as this preparation requires the use of 5%
dextrose as the diluent. Although a saline-induced diuresis appears
to be effective in reducing the incidence of RCIN (1) there is no
evidence for the efficacy or otherwise of 5% dextrose.
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